Blocking type 2 inflammation by dupilumab does not control classic (type 1‐driven) allergic contact dermatitis in chronic hand eczema

Crépy, Marie‐Noëlle; Nosbaum, Audrey; Bensefa‐Colas, Lynda

doi:10.1111/cod.13266

Cited by 25 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…63,64 Interestingly, in 1 case report, dupilumab administration resulted in the onset of recall dermatitis at the patch test site for colophony 24 hours after administration, suggestive of nonetype 2 immune pathways contributing to underlying dermatitis. 65 62 64 adults with AD 17 with PTþACD 14 with SACD 33 without ACD Retrospective study 64 7 adults with localized dermatitis refractory to dupilumab were PT 6 adults underwent PT before dupilumab Retrospective study 66 15 adults with AD with hand dermatitis and/or childhood AD had PT performed Retrospective study 63 48 adults with AD underwent PT Case report 65 42-year-old female with colophony allergy Case report 67 A 54-year-old surgeon with hand dermatitis refractory to dupilumab had a PT Case report 68 A 44-year-old man with nickel allergy to metal endovascular stents on MMF and prednisone After treatment, patients with PTþACD and SACD had similar decreases in BSA, IGA, and pruritus compared with those without ACD. All 7 patients had at least 1 positive PT result, with at least >1 or stronger reaction.…”

Section: Managementmentioning

confidence: 99%

A review of contact dermatitis

Brar¹

2021

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Nickel is the most common allergen, though many other sources of contact allergens are hidden in everyday products, such as preservatives and fragrances. In screening for contact allergy, it is important to inquire about environmental and occupational exposures, including wet work and mechanisms of irritation, such as frequent hand washing or wiping. The mechanisms of contact dermatitis are complex and may involve different T cell signaling pathways. Patch testing is required for diagnosis, and patch testing with patient's personal products is recommended. Management currently focuses on allergen avoidance, topical therapies, or corticosteroids; some biologics may be indicated for treatment.

show abstract

Section: Managementmentioning

confidence: 99%

A review of contact dermatitis

Brar¹

2021

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

show abstract

“…The annual incidence of contact dermatitis in most countries ranged from 5.7 to 101 cases per 100,000 employees/year. The most reliable studies estimate it between 11 and 86 cases per 100000 employees/year [12] [13]. Indeed, Ahn Y-S et al [14] estimated this incidence to be 78 cases per 100,000 workers in the United Kingdom, while in Singapore in 2007, Gan W-H et al [15] found an annual incidence of occupational contact dermatitis of 400/100,000 conscripts/year.…”

Section: Discussionmentioning

confidence: 99%

“…Another more rare location is the face [12], in particular the eyelids by airborne mechanism (volatile products) or due to contact with contaminated hands or gloves.…”

Section: Discussionmentioning

confidence: 99%

Occupational Allergic Contact Dermatitis in Tunisia: Epidemiology and Occupational Outcome

Aloui¹,

Maoua²,

Kalboussi³

et al. 2018

ODEM

View full text Add to dashboard Cite

Background: Occupational allergic contact dermatitis (ACD) is one of the most frequent diseases on the workplace worldwide. Its national incidence and prevalence were not previously studied in Tunisia. Objective: To assess incidence of occupational allergic contact dermatitis and its occupational outcome in Tunisia. Methods: Descriptive epidemiological study of all cases of occupational allergic contact dermatitis reported from 2002 to 2012 in Tunisia and recognized by the medical commissions of the National Health Insurance Fund. Results: 315 cases of occupational ACD were collected representing an annual incidence of 31.65 cases/100.000 workers in the private sector in Tunisia. The mean age of our population was 42.70 ± 9.02 years with a male predominance (sex ratio 3.03). The most affected sectors were the clothing sector (14.3% of cases) and the cement industry (13.7% of cases). Patch tests were positive in 188 patients (59.67%). The most frequently positive allergen was potassium dichromate in 27.3% of the cases. Overall, 25.4% of patients had lost their jobs. After multiple binary logistic regression, job loss had a statistically significant relationship with localization of lesions on the face and on dominant hand. Conclusion: Occupational ACD is frequent in Tunisia and is responsible for an important rate of job loss. Preventive measures must be reinforced, especially the wearing of protective gloves.

show abstract

“…However, recent case reports have also shown treatment failure of dupilumab for cases of occupational allergic and irritant contact dermatitis [ 14 , 15 ]. Our case series is the first to describe the long-term follow-up of up to 30 months in recalcitrant cases of both allergic and irritant occupation-related contact dermatitis.…”

Section: Discussionmentioning

confidence: 99%

Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series

et al. 2022

View full text Add to dashboard Cite

Background: Occupational contact dermatitis may progress to a chronic course with an unfavorable prognosis. Dupilumab has been shown to be effective as a treatment for moderate-to-severe atopic dermatitis as well as other types of dermatitis. Objectives: The aim of the study was to describe cases of chronic recalcitrant occupational contact dermatitis treated with dupilumab and with long-term follow-up. Methods: A retrospective review of 6 patients treated with dupilumab for chronic occupational contact dermatitis for periods of up to 30 months was performed. Results: All 6 patients had a positive and sustainable response, with dermatitis clearance and the ability to sustain work tasks. Conclusions: We report a case series of atopic and nonatopic workers with occupational chronic contact dermatitis who failed to achieve remission under various systemic modalities but did so using dupilumab. We suggest considering dupilumab treatment for recalcitrant occupational contact dermatitis.

show abstract

Blocking type 2 inflammation by dupilumab does not control classic (type 1‐driven) allergic contact dermatitis in chronic hand eczema

Cited by 25 publications

References 15 publications

A review of contact dermatitis

A review of contact dermatitis

Occupational Allergic Contact Dermatitis in Tunisia: Epidemiology and Occupational Outcome

Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series

Contact Info

Product

Resources

About